Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Protective Effect of SLNP on Hepatic Fibrosis Induced by Thioacetamide in Rats

Author(s): Lizhen Wu, Jinying Liu, Chongbo Zheng, Haijuan Ma, Xingling Cao, Zhihua Huang* and Keqiang Tian*

Volume 29, Issue 37, 2023

Published on: 02 November, 2023

Page: [2988 - 2995] Pages: 8

DOI: 10.2174/0113816128265631231025071732

Price: $65

Abstract

Introduction: The incidence of non-alcoholic fatty liver disease (NAFLD) has increased in recent years. Hepatic fibrosis (HF) is an important step in the progression of NAFLD to cirrhosis and even carcinoma and is also recognized as a possible reversal phase.

Aims: We previously found that the aqueous extract of Sedum Lineare Thunb. has hepatoprotective effects. This study investigated the hepatoprotective effect and mechanism of the Sedum Lineare Thunb. n-butanol phase (SLNP) on HF in rats.

Methods: Animals were intraperitoneally injected with thioacetamide solution twice a week for 8 weeks to prepare an HF model and were administered the corresponding drugs or an equal volume of normal saline by intragastric administration once a day for 8 weeks. Liver function, hydroxyproline and malondialdehyde (MDA) content, superoxide dismutase (SOD), Na+-K+-ATPase, and Ca2+-Mg2+-ATPase were analyzed using colorimetric methods. Moreover, mRNA expression and protein levels in the liver tissue were detected via quantitative polymerase chain reaction and western blotting, respectively.

Results: The results showed that SLNP could effectively improve the liver function of rats with HF and significantly reduce the content of hydroxyproline; the mRNA expression and protein levels of alpha-smooth muscle actin (α-SMA), collagen I, III, and IV, transforming growth factor beta 1 (TGF-β1), Smad2/3, and Smad4 were also significantly reduced. Simultaneously, SLNP significantly increased the activities of SOD, Na+-K+- ATPase, and Ca2+-Mg2+-ATPase in the rat liver tissues, whereas it reduced the levels of MDA and SOD in the serum and liver tissues.

Conclusion: This study revealed that SLNP elicits an anti-fibrotic effect by inhibiting oxidative stress and stellate cell activation, thereby reducing the formation and deposition of the extracellular matrix. The TGF-β1/Smads signaling pathway may be involved in this process.

« Previous Next »
[1]
Chinese Portal Hypertension Diagnosis and Monitoring Study Group (CHESS). [Consensus on clinical application of hepatic venous pressure gradient in China (2018)]. Zhonghua Gan Zang Bing Za Zhi 2018; 26(11): 801-12.
[PMID: 30616313]
[2]
Liu GQ, Wang DD, Yu MOW, et al. Protective effect of Cordyceps flower polysaccharides on mice with CCl4-induced liver fibrosis. J Hefei UniTechnol (Natural Science) 2022; 45(3): 411-16.
[3]
Wu BM, Liu JD, Li YH, Li J. Margatoxin mitigates CCl4-induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling. Int J Mol Med 2020; 45(1): 103-14.
[PMID: 31746414]
[4]
Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: From fundamental science to clinical applications. Nat Rev Mol Cell Biol 2021; 22(9): 608-24.
[http://dx.doi.org/10.1038/s41580-021-00373-7] [PMID: 34079104]
[5]
Shokravi S, Borisov V, Zaman BA, et al. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): A comprehensive review. Stem Cell Res Ther 2022; 13(1): 192.
[http://dx.doi.org/10.1186/s13287-022-02825-z] [PMID: 35527304]
[6]
Manka P, Zeller A, Syn WK. Fibrosis in chronic liver disease: An update on diagnostic and treatment modalities. Drugs 2019; 79(9): 903-27.
[http://dx.doi.org/10.1007/s40265-019-01126-9] [PMID: 31119644]
[7]
Li H. Advances in anti hepatic fibrotic therapy with traditional Chinese medicine herbal formula. J Ethnopharmacol 2020; 251: 112442.
[http://dx.doi.org/10.1016/j.jep.2019.112442] [PMID: 31891799]
[8]
Wei C, Qiu J, Wu Y, et al. Promising traditional Chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis). J Ethnopharmacol 2022; 297: 115550.
[http://dx.doi.org/10.1016/j.jep.2022.115550] [PMID: 35863612]
[9]
Li Z, Ouyang H, Zhu J. Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease. Front Pharmacol 2023; 14: 1195146.
[http://dx.doi.org/10.3389/fphar.2023.1195146] [PMID: 37361209]
[10]
Qin X, Wang X, Tian M, et al. The role of Andrographolide in the prevention and treatment of liver diseases. Phytomedicine 2023; 109: 154537.
[http://dx.doi.org/10.1016/j.phymed.2022.154537] [PMID: 36610122]
[11]
Zhou Q, Lian LF, Wu LZ, et al. Antitumor effect and immune mechanism of Sedum lineare on tumor-bearing mice. Pharmacol Clin Chin Mater Med 2013; 29(06): 83-6.
[12]
Wu LZ, Cao XL, Li HH, et al. Antitumor activity of sedum lineare thunb by suppressing oxidative stressand modulating tumor immune. Chongqing Med 2015; (19): 2613-5.
[13]
Zhou Q, Sui RY, Lian LF, et al. Effect of Sedum lineare Thunb on adjuvant arthritis in rats and its effect on inflammatory factors. Pharmacol Clin Chin Mater Med 2013; 29(04): 105-7.
[14]
Liao YH, Wu LZ, Cheng GZ, et al. Anti-inflammatory effect of sedum lineare in mice. Zhongguo Shiyan Fangjixue Zazhi 2011; 17(3): 142-4.
[15]
Zhou L, Cao XL, Xiong XQ, et al. Effect of Sedum lineare on lipid peroxidation in rats with liver fibrosis. Zhongguo Shiyan Fangjixue Zazhi 2010; 16(16): 174-7.
[16]
Zhou Q, Yang QC, Cheng GZ, et al. The effect of Sedum lineare on rat’s hepatic fibrosis induced by CCl4. Pharmacol Clin Chin Mater Med 2011; 27(1): 70-3.
[17]
Wang X, Ma H, Xue M, et al. Anti-nociceptive effects of Sedum lineare Thunb. on spared nerve injury-induced neuropathic pain by inhibiting TLR4/NF-κB signaling in the spinal cord in rats. Biomed Pharmacother 2021; 135: 111215.
[http://dx.doi.org/10.1016/j.biopha.2020.111215] [PMID: 33418303]
[18]
Luo P, Liu D, Zhang Q, et al. Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1. Acta Pharm Sin B 2022; 12(5): 2300-14.
[http://dx.doi.org/10.1016/j.apsb.2021.12.007] [PMID: 35646542]
[19]
Huang P, Ma H, Cao Y, et al. Activation of primary hepatic stellate cells and liver fibrosis induced by targeting TGF-β1/Smad signaling in schistosomiasis in mice. Parasit Vectors 2022; 15(1): 456.
[http://dx.doi.org/10.1186/s13071-022-05584-1] [PMID: 36474240]
[20]
Cao S, Zheng B, Chen T, et al. Semen Brassicae ameliorates hepatic fibrosis by regulating transforming growth factor-β1/Smad, nuclear factor-κB, and AKT signaling pathways in rats. Drug Des Devel Ther 2018; 12: 1205-13.
[http://dx.doi.org/10.2147/DDDT.S155053] [PMID: 29785090]
[21]
Xie J, Li X, Zhang L, et al. Genistein-3′-sodium sulfonate ameliorates cerebral ischemia injuries by blocking neuroinflammation through the α7nAChR-JAK2/STAT3 signaling pathway in rats. Phytomedicine 2021; 93: 153745.
[http://dx.doi.org/10.1016/j.phymed.2021.153745] [PMID: 34634743]
[22]
Ma HJ, Cao XL, Huang ZH. Research progress on pharmacological effects and mechanism of Sedum lineare Thunb. J Gannan Med Univ 2019; 39(8): 833-6.
[23]
Niu X, Yao H, Li W, et al. δ-Amyrone, a specific inhibitor of cyclooxygenase-2, exhibits anti-inflammatory effects in vitro and in vivo of mice. Int Immunopharmacol 2014; 21(1): 112-8.
[http://dx.doi.org/10.1016/j.intimp.2014.04.019] [PMID: 24813716]
[24]
Tian LW, Su JW, Zhong C, et al. Study on the chemical conitituents of Sedum lineare. Chin Pharm 2016; 27(21): 2956-8.
[25]
Niu X, Yao H, Li W, et al. δ-amyrone inhibits lipopolysaccharide-induced inflammatory cytokines and protects against endotoxic shock in mice. Chem Biol Interact 2015; 240: 354-61.
[http://dx.doi.org/10.1016/j.cbi.2015.07.007] [PMID: 26271896]
[26]
Trivedi P, Wang S, Friedman SL. The power of plasticity-metabolic regulation of hepatic stellate cells. Cell Metab 2021; 33(2): 242-57.
[http://dx.doi.org/10.1016/j.cmet.2020.10.026] [PMID: 33232666]
[27]
Fu M, Yin W, Zhang W, Zhu Y, Ni H, Gong L. MicroRNA-15a inhibits hepatic stellate cell activation and proliferation via targeting SRY-box transcription factor 9. Bioengineered 2022; 13(5): 13011-20.
[http://dx.doi.org/10.1080/21655979.2022.2068895] [PMID: 35611752]
[28]
Chen C, Chen J, Wang Y, et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling. Phytomedicine 2023; 110: 154626.
[http://dx.doi.org/10.1016/j.phymed.2022.154626] [PMID: 36603342]
[29]
Zhao X, Amevor FK, Xue X, et al. Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: A comprehensive review. J Nanobiotechnol 2023; 21(1): 121.
[http://dx.doi.org/10.1186/s12951-023-01876-5] [PMID: 37029392]
[30]
Zhang B, Lai L, Tan Y, et al. Hepatoprotective effect of total flavonoids of Mallotus apelta (Lour.) Muell.Arg. leaf against carbon tetrachloride-induced liver fibrosis in rats via modulation of TGF-β1/Smad and NF-κB signaling pathways. J Ethnopharmacol 2020; 254: 112714.
[http://dx.doi.org/10.1016/j.jep.2020.112714] [PMID: 32105750]
[31]
Lam P, Cheung F, Tan H, Wang N, Yuen M, Feng Y. Hepatoprotective effects of Chinese medicinal herbs: A focus on anti-inflammatory and anti-oxidative activities. Int J Mol Sci 2016; 17(4): 465.
[http://dx.doi.org/10.3390/ijms17040465] [PMID: 27043533]
[32]
Toyoshima C, Cornelius F. New crystal structures of PII-type ATPases: Excitement continues. Curr Opin Struct Biol 2013; 23(4): 507-14.
[http://dx.doi.org/10.1016/j.sbi.2013.06.005] [PMID: 23871101]
[33]
Kartasheva-Ebertz D, Gaston J, Lair-Mehiri L, et al. IL-17A in human liver: Significant source of inflammation and trigger of liver fibrosis initiation. Int J Mol Sci 2022; 23(17): 9773.
[http://dx.doi.org/10.3390/ijms23179773] [PMID: 36077175]
[34]
Zaafan MA, Abdelhamid AM. Dasatinib ameliorates thioacetamide-induced liver fibrosis: Modulation of miR-378 and miR-17 and their linked Wnt/β-catenin and TGF-β/Smads pathways. J Enzyme Inhib Med Chem 2022; 37(1): 118-24.
[http://dx.doi.org/10.1080/14756366.2021.1995379] [PMID: 34894966]
[35]
Xiao T, Gao D, Gu X, et al. Flavokawain A ameliorates pulmonary fibrosis by inhibiting the TGF-β signaling pathway and CXCL12/CXCR4 axis. Eur J Pharmacol 2023; 958: 175981.
[http://dx.doi.org/10.1016/j.ejphar.2023.175981] [PMID: 37579968]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy